Loading…
← CockpitCompetitor Analysis › 603567.SS HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

HeiLongJiang ZBD Pharmaceutical Co., Ltd. Class A603567.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum laggard 12
Mkt cap
$610M
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$12.6M
20-day average traded
Fwd P/E
5.4×
forward earnings
ROIC−WACC
n/a
WACC 5.0%
Hurdle
+34 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥4.42
1D-1.8%
1W-11.6%
1M-11.8%
3M-37.0%
6M-39.3%
YTD-50.5%
1Y-61.6%
ATR %4.5%
52w lowhigh62.9% off high

What HeiLongJiang ZBD Pharmaceutical does

Employees: 1,961

HeiLongJiang ZBD Pharmaceutical at a glance

Size HeiLongJiang ZBD Pharmaceutical (603567.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $610M, the 3201st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.42 on 18 Nov 2026.

Performance Over six months the shares fell 39.3%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 20 in its peer set.

Growth Revenue fell 82.0% over the last twelve months (peer median +4.6%).

Valuation It trades at 5.4× forward earnings against a peer median of 11.4× (cheapest of 6).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -25%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 75603567.SS 61
Six months, rebased to 100: HeiLongJiang ZBD Pharmaceutical against the median of its 20 peers (local-currency closes).

HeiLongJiang ZBD Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥286MCN¥796MCN¥2.69BCN¥3.13BCN¥4.20B
Revenue growth—-70%-14%-26%—
Gross profitn/a-CN¥71.4MCN¥1.40BCN¥1.24BCN¥639M
EBITDAn/a-CN¥1.31BCN¥774MCN¥303M-CN¥108M
Net income-CN¥1.48B-CN¥1.37BCN¥438MCN¥473MCN¥185M
Free cash flowCN¥198MCN¥254M-CN¥1.42M-CN¥553M-CN¥679M
Capital expenditureCN¥30.1MCN¥68.5MCN¥189MCN¥95.1MCN¥404M
Total debtCN¥3.14BCN¥3.14BCN¥3.36BCN¥3.26BCN¥3.05B

Quarterly statements and history in the cockpit →

HeiLongJiang ZBD Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-50%0%+50%002940002793185750300194ORCHPHARMA4105DBV300233OLMA301211301096600976BCAXIMMX300147300878CGEM603567.SS6-month return →1-month return →
Up and to the right = strong over both horizons. HeiLongJiang ZBD Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-75%-50%-25%0%0×25×50×75×185750ORCHPHARMA4105301096600976603567.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HeiLongJiang ZBD Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%00294000279318575030019441053002333001474123603567.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HeiLongJiang ZBD Pharmaceutical is the large dot.

HeiLongJiang ZBD Pharmaceutical competitors and peer comparison

How HeiLongJiang ZBD Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HeiLongJiang ZBD Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603567.SSPeer medianRank in peer set
1-month return-11.8%-10.2%9th lowest of 20
6-month return-39.3%-26.6%6th lowest of 20
Distance from 52-week high-62.9%-41.0%3rd lowest of 20
Revenue growth (TTM)-82.0%+4.6%lowest of 15
Forward P/E5.4×11.4×cheapest of 6
Growth the price implies (Req g, 7 yrs)9.1%-0.6%5th most demanding of 10
Growth delivered (Del g)-25.1%+2.1%lowest of 10
Hurdle (Req g minus delivered)+34.2 pp+8.1 pp2nd most demanding of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a5.4×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%n/a10.1%+2.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%n/a-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%11.4×-6.6%+5.4%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%n/a10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%83.1×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%10.2×-8.7%+8.8%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%n/a-0.6%-1.6%
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%n/an/an/a
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%54.0×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%6.7×-6.2%+6.5%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%n/an/an/a
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%n/a50.4%-12.3%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%n/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%n/a36.3%+16.2%

Questions

Which companies are HeiLongJiang ZBD Pharmaceutical's closest peers?
The cockpit's peer set: Zhejiang Anglikang Pharmaceutical (002940.SZ), Achieve Life Sciences (QUIT), Luoxin Pharmaceuticals Group Stock (002793.SZ), Chongkundang (185750.KS), Fuan Pharmaceutical (Group) (300194.SZ), Orchid Pharma (ORCHPHARMA.NS), TTY Biopharm (4105.TWO), DBV Technologies (DBV.PA).
Is HeiLongJiang ZBD Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 5.4× against a peer median of 11.4×, cheapest of 6 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is -25%, so the hurdle is +34 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has HeiLongJiang ZBD Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -39.3% against -26.6% for the median peer; over one year -61.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.